• FY24 Labor, HHS, and Education appropriation bill related to funding for biomedical research, NBCCEDP, cancer prevention and control, and related cancer services and report language related to access to supplemental and diagnostic breast imaging FY25 Labor, HHS, and Education appropriation bill related to funding for biomedical research, NBCCEDP, cancer prevention and control, and related cancer services and report language related to access to supplemental and diagnostic breast imaging FY25 Presidents Budget Proposal related to funding for biomedical research, NBCCEDP, cancer prevention and control, and related cancer services and report language related to access to supplemental and diagnostic breast imaging Policies related to transparent use of artificial intelligence, via patient notification, and validation of its use, scaling and outcomes in breast cancer screening Policies related to supplemental and diagnostic breast imaging
• H.R. 2851/S. 2464 - Access to Breast Cancer Diagnosis Act of 2023; bill to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations H.R. 6301/S. 2039 - Cancer Drug Parity Act; a bill to amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. H.R. 830/S. 1375 -Help Ensure Lower Patient (HELP) Copays Act; bill requires health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. H.R. 2630/S. 652 -Safe Step Act; bill to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes H.R. 3086 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals at greater risk for breast cancer. H.R. 4189/S. 2016 - Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; a bill to amend title XVIII of the Social Security Act to expand access to telehealth services, and for other purposes. H.R. 824 - Telehealth Benefit Expansion for Workers Act of 2023; bill expanding exception for stand-alone telehealth benefits plans from certain requirements that generally apply to private health insurance plans under the Patient Protection and Affordable Care Act; under the bill employers may offer stand-alone telehealth benefits to all employees including those who are eligible for enrollment in their employers group health plan H.R. 2868 - Association Health Plans Act; a bill to amend the Employee Retirement Income Security Act of 1974 to clarify the treatment of certain association health plans as employers, and for other purposes Comments regarding US District Court Decision on 2021 Notice on Benefit and Payment Parameters Implementation of the No Surprises Act including comments on proposed rule re: Federal Independent Dispute Resolution Operations Comments related to the 2025 Notice on Benefit and Payment Parameters (CMS-9895-P) Comments in response to House Education & Workforce RFI on Employee Retirement Income Security Act (ERISA) Administration actions necessary to reduce out-of-pocket costs for medically necessary diagnostic and supplemental breast imaging Administrative actions necessary to reduce out-of-pocket costs for medically-necessary diagnostic breast imaging Implementation of the Affordable Care Act and coverage of preventive services with no cost-sharing Issues related to regulation of short-term limited duration plans Issues related to prescription drug affordability for patients Policies regarding White House Cancer Moonshot implementation Policies related to copay accumulator and adjustor programs
• H.R. 549/S. 663 -Metastatic Breast Cancer Access to Care Act; a bill to exempt individuals with metastatic breast cancer from certain waiting periods for disability insurance benefits under the Old-Age, Survivors, and Disability Insurance program and related Medicare coverage H.R. 1526/S. 765 -Reducing Hereditary Cancer Act of 2023; bill provides for Medicare coverage of germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation or suspected history of hereditary cancer, as well as for associated coverage of risk-reducing surgeries and screenings H.R. 1780/S. 642 - Finn Sawyer Access to Cancer Testing Act; bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer. H.R. 2407/S. 2085 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; bill allows for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. H.R. 3086 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals at greater risk for breast cancer. H.R. 4189/S. 2016 - Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; a bill to amend title XVIII of the Social Security Act to expand access to telehealth services, and for other purposes. H.R. 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act ; would ensure Medicare beneficiaries receive prompt care and services from pharmacists to prevent, diagnose, and treat common infectious diseases. S. 3892 - Community Health Worker Access Act; a bill to amend titles XVIII and XIX of the Social Security Act to increase access to community health workers under the Medicare and Medicaid programs. H.R. 3876/S .2323 - Access to Genetic Counselor Services Act of 2023; This bill provides for coverage under Medicare of genetic counseling services that are furnished by genetic counselors. Covered services include those services, as well as incidental services and supplies, that would otherwise be covered under Medicare if provided by a physician. Comments Related to OIG Solicitation New and Modified Safe Harbors and Special Fraud Alerts OIG-1123-N, 88 Fed. Reg. 84116 requesting permission for sponsors of clinical trials targeting cancer or other life-threatening diseases or conditions to cover certain indirect costs incurred by clinical trial participants. Comments Related to CMS Enforcement of State Compliance with Reporting and Federal Medicaid Renewal Requirements Under Section 1902(t) of the Social Security Act (CMS-2447-IFC) Comments related to processes for assessing compliance with Mental Health Parity and Addition Equity in Medicaid and CHIP Comments related to Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies Comments RE: Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025 Medicare coverage policy for breast cancer treatments and services Proposed waivers under Sections 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Medicaid unwinding and the process for redetermination of Medicaid eligibility Policies related to the imposition of work requirements within the Medicaid program Policies related to PBM reform Policy related to medical billing for breast reconstruction surgery called DIEP flap, a type of natural tissue breast reconstruction that uses non-breast tissue to replace breast tissue Policies related to the implementation of the Inflation Reduction Act Policies related to the implementation of the Lymphedema Treatment Act
• FY24 Funding and issues pertaining to the congressionally-directed medical research program, especially those relating to breast cancer FY25 Funding and issues pertaining to the congressionally-directed medical research program, especially those relating to breast cancer H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; a bill which authorizes FY2024 appropriations and sets forth policies for Department of Defense (DOD) programs and activities, military construction, and the national security programs of the Department of Energy
• H.R. 2916/S. 1840 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2023; bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 1092/S. 562 -Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act; requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act; To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 4363/S. 2213 - Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivor's background, or forthcoming survivorship needs, and for other purposes. S. 2243 - Palliative Care and Hospice Education and Training Act; a bill amend the Public Health Service Act to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools and other programs, including social work, physician assistant, and chaplaincy education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative and hospice care. S. 2140 - Patient Eligibility Restoration Act; a bill to amend the law relating to patent subject matter eligibility to establish that only specified subject matter (e.g., a natural process wholly independent of human activity) is ineligible for patenting. Comments related to healthcare affordability Efforts related to breast screening recommendations by the United States Preventative Services Taskforce Efforts to preserve protections in the Affordable Care Act (ACA) for LGBTQ+ patients Policies related to ICD-10 codes for inflammatory breast cancer Policies related to sterile injectable medications shortages Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to genetic counseling and testing Policies to increase clinical trial diversity and access for underrepresented populations Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to reforms to the United States Preventative Services Taskforce

Duration: April 1, 2015 to present

General Issues: Budget/Appropriations, Insurance, Medicare/Medicaid, Defense, Health Issues, Taxation/Internal Revenue Code

Spending: about $2,471,348 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2015: U.S. Senate, House of Representatives, White House Office, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Internal Revenue Service (IRS), Office of Personnel Management (OPM), Centers For Medicare and Medicaid Services (CMS), Treasury - Dept of, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC), Agency for Healthcare Research & Quality (AHRQ), Consumer Financial Protection Bureau (CFPB), Vice President of the U.S., Defense - Dept of (DOD)